Tilray(TLRY) Seeking Alpha·2024-10-08 10:00Analyst's Perspective - The analyst initiated coverage of Tilray Brands Inc (NASDAQ: TLRY) with a buy rating in March, driven by Germany's new cannabis law that facilitates easier access to medical cannabis products for patients [1] - The analyst leverages experience as a former managing editor at a financial media publication focused on mid and small caps, combined with an academic background in financial markets and institutions, to identify investment opportunities in undervalued companies [1] - The analyst emphasizes thorough research and analysis of financial statements, market trends, and upcoming events that may impact specific companies or industries [1] Disclosure and Context - The analyst has no stock, option, or derivative positions in the mentioned companies and no plans to initiate such positions within the next 72 hours [2] - The article reflects the analyst's personal opinions and is not influenced by compensation or business relationships with the mentioned companies [2] - Seeking Alpha clarifies that its analysts are third-party authors, including both professional and individual investors, who may not be licensed or certified by any regulatory body [3]